Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Staccato Apomorphine Safety and PK/PD in Parkinson's Disease
NCT04157933Phase 1Completed
- Sponsor
- Alexza Pharmaceuticals Inc
- Start
- Oct 2019
- Primary completion
- Feb 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of apomorphine in Parkinson's disease (PD) (6 arms), sponsored by Alexza Pharmaceuticals Inc. Primary endpoints: Dose Proportionality of multi-dose inhaled apomorphine by Power Analysis of AUC at 6 days, Effect on MDS-UPDRS in Parkinson's disease OFF periods at 2 days and 2 more. Started Oct 2019; status: completed.
02
Drugs
apomorphine
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04157933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04157933.